Straight from the hood to streets
Chris Boshoff, top oncology executive, counts on gains from the $43 billion Seagen merger.
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website
Save my name, email, and website in this browser for the next time I comment.
Leave a Reply